Market Place
Sourcing Support
Enlivex Receives Regulatory Nod For Allocetra TMJ Osteoarthritis Trial
11 Dec 2024 //
GLOBENEWSWIRE
Enlivex Announces Positive Data from Allocetra Trial for Knee OA
03 Dec 2024 //
GLOBENEWSWIRE
Enlivex Adopts Bitcoin Treasury Reserve Strategy
20 Nov 2024 //
GLOBENEWSWIRE
Enlivex Doses First Patient in Psoriatic Arthritis Phase I Trial
14 Nov 2024 //
GLOBENEWSWIRE
Enlivex Doses First 10 Patients in Allocetra Knee OA Trial
12 Nov 2024 //
GLOBENEWSWIRE
Enlivex Receives Japanese Patent for Allocetra™ in OA
30 Oct 2024 //
GLOBENEWSWIRE
Enlivex Receives Authorization For Phase II Trial Of Allocetra
26 Sep 2024 //
GLOBENEWSWIRE
Enlivex Gets Positive DSMB for Phase II Allocetra Trial
24 Sep 2024 //
GLOBENEWSWIRE
Enlivex Authorized To Start Phase I Trial Of Allocetra In Psoriatic Arthritis
23 Jul 2024 //
GLOBENEWSWIRE
Enlivex Begins Phase I/II Trial of AllocetraTM in Thumb Osteoa
24 Jun 2024 //
GLOBENEWSWIRE
Enlivex Therapeutics CEO To Host Live Investor Webinar And Q&A On June 25
20 Jun 2024 //
GLOBENEWSWIRE
Enlivex Announces +ve Interim Data From Ph I/II Trial Of Allocetra In Knee OA
17 Jun 2024 //
GLOBENEWSWIRE
Enlivex`s Allocetra Placebo Trial In Thumb Osteoarthritis Authorized
03 Jun 2024 //
GLOBENEWSWIRE
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
29 May 2024 //
GLOBENEWSWIRE
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
28 May 2024 //
GLOBENEWSWIRE
Enlivex Doses First Allocetra Knee Osteoarthritis Patients
22 Apr 2024 //
GLOBENEWSWIRE
Enlivex Authorized for Allocetra Phase I/II Trial in Knee Osteoarthritis
16 Apr 2024 //
GLOBENEWSWIRE
Enlivex’s Stock Plummets 50% on Phase II Sepsis Results for Cell Therapy
13 Apr 2024 //
BIOSPACE
Enlivex Topline Phase 2 Allocetra Results In Sepsis Patients
11 Apr 2024 //
GLOBENEWSWIRE
Enlivex Webcast 4/12 On Phase 2 Allocetra Sepsis Trial Results
11 Apr 2024 //
GLOBENEWSWIRE
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells
07 Feb 2024 //
GLOBENEWSWIRE
Enlivex Receives Authorization for Initiation of Ph I/II Evaluating Allocetra
17 Jan 2024 //
GLOBENEWSWIRE
Enlivex Announces Completion of Enrollment of Ph II Trial Evaluating Allocetra
20 Dec 2023 //
GLOBENEWSWIRE
Enlivex lays off 50% of staff; Moderna warns against TRC Capital
11 Sep 2023 //
ENDPTS
Enlivex Announces Reprioritization Plan & Second Quarter 2023 Financial Results
11 Sep 2023 //
GLOBENEWSWIRE
Enlivex to Present at H.C. Wainwright 25th Annual Global Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of PII Evaluating Allocetra
31 Jul 2023 //
GLOBENEWSWIRE
Enlivex Announces Q1 2023 Financial Results and Provides a Business Update
26 Jun 2023 //
GLOBENEWSWIRE
Enlivex to Present at the 2023 Jefferies Healthcare Conference
06 Jun 2023 //
GLOBENEWSWIRE
Enlivex Selected for an Elevator Pitch Presentation
31 May 2023 //
GLOBENEWSWIRE
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra
08 May 2023 //
GLOBENEWSWIRE
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering
19 Apr 2023 //
GLOBENEWSWIRE
Enlivex Appoints Andrew Singer to its Board of Directors
17 Apr 2023 //
GLOBENEWSWIRE
Enlivex Announces Tislelizumab Collaboration, Full Year Financial Results
04 Apr 2023 //
GLOBENEWSWIRE
Enlivex, BeiGene Partner to Evaluate Allocetra/PD-1 Inhibitor Tislelizumab
03 Apr 2023 //
CONTRACT PHARMA
Enlivex Announces Collaboration to Evaluate Combinations of Allocetra & Tislelizumab
03 Apr 2023 //
GLOBENEWSWIRE
Enlivex Receives Positive DSMB Recommendation to Continue P I/II
20 Mar 2023 //
GLOBENEWSWIRE
Enlivex Receives Clearance For Advanced Solid Malignancies in PI/II Trial
23 Feb 2023 //
GLOBENEWSWIRE
Enlivex Announces Issuance of Patent Covering Use of Allocetra to Prevent CRS
15 Feb 2023 //
GLOBENEWSWIRE
Enlivex Announces DSMB Recommendation to Continue PI/II Trial of Allocetra
25 Jan 2023 //
GLOBENEWSWIRE
Enlivex Receives Authorizations from Agencies To Expand PII Sepsis Trial
04 Jan 2023 //
GLOBENEWSWIRE
Enlivex Receives Allocetra IND Clearance From The U.S. FDA
28 Nov 2022 //
GLOBENEWSWIRE
Enlivex Announces Dosing of First Patient in PI/II Trial Evaluating Allocetra
15 Nov 2022 //
GLOBENEWSWIRE
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
03 Oct 2022 //
GLOBENEWSWIRE
Enlivex to Present at Upcoming Investor and Media Conferences
13 Sep 2022 //
GLOBENEWSWIRE
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing
12 Sep 2022 //
GLOBENEWSWIRE
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering
29 Aug 2022 //
GLOBENEWSWIRE
Enlivex Announces Regulatory Clearance for Frozen Allocetra Formulation
24 Aug 2022 //
GLOBENEWSWIRE
Enlivex Announces Second Quarter 2022 Financial Results
22 Aug 2022 //
GLOBENEWSWIRE
Enlivex receives approval for Phase I/II solid tumour trial in Israel
18 Aug 2022 //
CLINICALTRIALSARENA
Enlivex Receives Approval for the PI/II Trial Evaluating Allocetra
17 Aug 2022 //
GLOBENEWSWIRE
Enlivex Receives Notice of Allowance for U.S. Patent Application of Allocetra
03 Aug 2022 //
GLOBENEWSWIRE
Sheba, Enlivex Begins Dosing in PI/II Trial of Allocetra + Chemotherapy
06 Jul 2022 //
GLOBENEWSWIRE
Enlivex to Present at the 2022 Jefferies Healthcare Conference
07 Jun 2022 //
GLOBENEWSWIRE
Enlivex Receives Israeli MHA for Initiation of PI/II Trial of Allocetra
06 Jun 2022 //
GLOBENEWSWIRE
Enlivex Announces New Preclinical Data in Ovarian Cancer on Survival Benefit
31 May 2022 //
GLOBENEWSWIRE
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant
25 May 2022 //
PRESS RELEASE
Enlivex Appoints Dr. Roger J. Pomerantz to Board of Directors as Vice Chairman
23 May 2022 //
GLOBENEWSWIRE
Enlivex to Present at the H.C. Wainwright Global Investment Conference
19 May 2022 //
GLOBENEWSWIRE
